The IARC evaluates carcinogenicity through a rigorous process involving a comprehensive review of the existing scientific literature. This includes epidemiological studies, animal research, and mechanistic data. A panel of experts assesses the strength and quality of the evidence before classifying an agent. For substances with limited or conflicting evidence, such as those in Group 3, further research is often recommended.
